HIV l-Base
(A company limited by guarantee)
REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
Charity No: 1081905
Company No: 03962064

HIV l-Base
Contents
Page
Report oflhe trustees
Independent examinerfs report
Statement of financial activities
10
Balance sheet
Cash Flow Statement
12
Notes to the financial statements
15-21

HIV l-Base
Report of the trustees
Year ended 31 MARCH 2025
REFERENCE AND ADMINISTrAnVE DETAILS
Registsred Company number
03962064
Registered Charity number
1081905
Registsred office
2nd Floor. Regis House
45 King William Street
London
EC4R 9AN
Trustees
H Mhereza-mitchell
W F M Stokes
C Decle
Independent examiner
J Howard FCA
A2els Audit Servi￿s Limited
2nd Floor, Regis House
45 King William Street
London
EC4R 9AN
Bankers
National We5trnin5ter Bank plc
PO Box 83
Tavi%tock House
Tavi5tock Square
London
WC1H 9JA
Key management personnel as at 31 March 2025
Simon Collins

HIV14ase
Report of the trustees
Year ended 31 MARCH 2025
The trustees, who are also directors of the charity for the purpose of the Companies Act 2006, present their report with
financial statements of charity for the year end 31 March 2025. The trustees have adopted the provisions of Accounting
and Reporting by Charities.. Statement of Recommended Practi￿ applicable lo charities preparing their accounts in
accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 leffeclive 1
January 20151.
0￿ECTIVEs AND ACTIVITIES
The objectives of the charty are the protection and preservation of public health and for the relief of sickness by
disseminab.ng lo general prath"b"oners and other health care professionals. the resutts of research and other
infomiation concerned with the causes, the transmission and the Ireatrnenl of Human Imrnunodefic￿nCy Virus IHIW,
and related conditions so as lo improve the treatment of people living with HIV and prevent the transmission of HIV
and related conditions., by providing infomation, advi￿ and other assistan￿ lo those with HIV or related conditions
and lo their families and carers and to benefit individuals. both nab"onally and internationally,. through di%seminalion of
up-104ate medical and social information related to the treatment and prevention of HIV and other related health
issues.
A commitment lo the public benefit wthin the obj-eth.ves and activib.es of the organisab.on indudes a belief that..
People INing with HIV who understsnd HIV treatment and prevention are more likely to be adherent lo and
benefit from these strategies.
People living with HIV on SU￿$sful Ireaknenl can ￿ad working INes and contribute lo society in many ways.
People lThiing with HIV with undetectable viral load on treatment have a zero risk of transmith.ng HIV their
partners and almost zero risk of transmitting HIV to their infants lin the case of mothers with HIW - giving
enomious benefit to Indiv￿ua1S and public heaKh.
HIV negative people can also use antiretrowraLs lo redu￿ their risk of becoming HIV positi've- also conferring
benefits lo indNiduals and public health.
The charity activities to achieve these objectwes indude the followng projects.
HIV Treatsnenl BUl￿tin IHTBI, a technical review of the latest medical research aimed al doctors and other
healthcare professionals and distributed by email and online.
A range of non-technical Ireabmenl guides, wth easy-to-understand infomation for people living with HIV
and people at risk of HIV. Distribution is online and in printed format to indNiduals, HIV diniLS and
community organisations. These are regularly updated.
An Open-aC￿$S free treatment infomalion Selv￿ by email, post and telephone and online, answering more
than 5.000 quesb.ons each year.
A website broadening access lo our publications and archives and publirysing our acb"vib"es. Al publications
are available online as html pages and PDF fomiaL
Working with researcher5 as community representatives and advisors.
National and intemational advocacy work induding. policy and technical input to treatment and prevention
guidelines, clinical trials and dwg devekjpment. We serve on community advisory boards. guideline writing
groups and trial steering committees to ensure that the needs of people living with HIV are represented.
Engaging with national and international research groups and guidelines panels.
As part of restructuring this year, these projects were completed during the year and are no longer active.
Fil for Purpose- a review of the latest research and developments in optimised HIV treatment for low- and
middle-income ￿lUntrIeS {LMICsl.
Modem ART for South Africa- treatment and research infomiation for adivists from South Africa - including
printed materials, app, website, videos and training.
A series of small A7 pocket leaflets with less text than the guides. also distributed free to HIV clinics.
UK CAB community network to provide education training for people living wth HIV and their advocates.
Supporting AfroCAB to develop a similar community network lo UKCAB across several African countries.

HIV l-Base
Report of the trustees
Year ended 31 MARCH 2025
ACHIEVEMENT AND PERFOR￿NcE
Review of a¢tivitigS
HIV i-Base is a treatrnent actmst group, led by people living with HIV and committed to providing timely HIV Irealmenl
infomiation both lo healthcare professionals and to p*ople liwng with HIV and their advocates. HIV i-Base was fomed
in March 20CH) and has continued to report the most innovatsve and important medical advances in HIVIAIDS.
2025 is our 26th year as a charity-
HIV14ase Projects
Publications
During the period, we continued lo produce HIVTreatsnenl Bulletin {HTBI, and our community publications. HTB is now
a news stream rather than a compiled monthly publication. 11 is supported by a￿rtS for the most important reports on
soryal media platfornis.
HTB is distributed to approximately 1600 email subscribers, wilh a￿deS also distributed in email bulletins to roughly
1000 members of CHIVA and BHIVA. It is also aC￿sSed direcdy from the i-Base website. Articles are also publicised
on soaal media.
We continued dislribuling the remaining printed stod(s of the non-technical guides bLrt also made decided to primarily
focus on online publishing. Although sexual health clinics still value and want printed resources, these have become
increasingly drfficult lo fund. This deasion is also related lo i-Base moved from a physical lo a virtual working offi￿.
One exception is the UK Guide lo PrEP which, thanks to a small grant, wll continue to be printed and distributed f￿e
lo clinics.
Although remaining print stocks of treatment guides were distributed until August, demand for publications still
continued. We mel this need by dislribubng posters and post-cards with QR codes bul continue lo fundraise for some
print reSoUr￿S including the UK guide to PrEP. This year the PrEP guide was particularly important for reporting
planned updates lo the UK PrEP guidelines. A print run of 20.000 of these guides was distributed to UK clinic3 between
April and August. From September lo March we distributed 500 A4 posters and 8000 A6 postcards that included QR
codes lo this online guide.
All the key guides continue to be routinely updated online.
Support to clinical research and comrnunty outreach
Community involvement in clinical resea￿h
Several stsff continued to be involved as community representstives with several research groups, including on
guidelines panels, trial steering committees and advisory boards.
This involvement helps bridge the gap between re5earcher5 and the Ix*mmunitES that their research is hoping to
benefit. We help ensure greater aWa￿nesS of Ihe issues that affecl each group and active involvement of other
community advocates in these netsvorks.
This area has increased in re￿nt years and indudes involvement in a number of important intemab.onal studies. This
has also been one ofthe key aims for the UK-CAB.
During 2024-25, advocates al i-Base were involved in the DolPHIN 1 and 2 studies, ODYSSEY study, the INSIGHT
network, International ADS Society I￿S) Cure Working Group. Long-AclinglExtended Release Anlirelroviral Research
Resour￿ Program ILEAPI, the POPPY study, Public Health England IPHEI, UK-CHIC Database, UK Drug Resislan
Database, the RIO Study Icure-related research using bNAbsl. the SIMFT study {with semaglutide) and the Liverpool
University Drug 1nleracts.on website.
We were also involved in the CADO and PADO {adult and paediatric treatment optimisation groups), the AWG, PAWG
ladult and paedialrie ants'retroviral working groups) and HIV pregnancy working groups and of the WHO HIV
departmenL

HIV14ase
Report of thg trustses
Year ended 31 MARCH 2025
ACHIEVEMENT AND PERFORMANCE- continued
We infomially supported other research groups advi￿ on parbapant infomialion material and study design.
i-Base advocates were also involved as comrnunity representatives or in fomially commenting on national and
intemational guidelines panels induding this year the European HIV tymphoma guidelines.
i-Base advocates are usualty contn"bvting authors on more than 20 peer-reviewed papers or conference presentstions
each year.
Meetings. workshops and training UK
We continued to run treatment workshops with community groups in the UK induding as part of the UK-CAB
programme.
The UK£AB
i-Base founded the UK-CAB in 2002 and continued to pro￿de administrative support for more than 20 years. This has
been a highly Suc￿$sful project and now connects more than 700 advocates, broadly reffecting the UK demographics.
Approximately 40°k of members are women and 40.kn are fr(Kn migrant populations.
Part of restructuring pBase this year inVo￿ed finding a new organisalion to provide administrative support for the UK-
CAB. We were very lucky lo transfer the UK-CAB lo Positively UK al the end ofAugusl 2025. We were able lo do this
with the active support of the UK-CAB chair. sleeriThJ group and wider membership.
i-Base are proud of the role we have had to develop and support the UK-CAB for so long and we are very happy and
confident that il will continue lo be a vibrant and essential organisation with PosilNe UK.
UK-CAB meetings
i-Base organised ￿ UK-CAB training meetings this year in May and August before the handover.
May 2024- UK-CAB meeting after the BHIVA Spring conferen￿ (Bimiinghaml
August 2024 - Cognitive impaimient, Viiv Healthcare and IAS 2024 confe￿n￿ fe￿￿back (London)
All presentations and materials from these meetings are online".
htt s=Ilukcab.neVmeetin
sl ast-meetin
s-archivel
UK-CAB forurn
From April to August 2024, the members forum continued to be a foojs for discussions on a wide range of treatrnenl
related topics. The CAB also co-ordinated wider community responses lo the approval pr￿5$ for new drug approvals
and developing topics for the community sessions at the BHIVA conference.
Forum discussions covered all aspects of HIV care including treatsnenl updates and questions, HIV cure research
including the RIO and other studies, conferen￿, webinars and other HIV online training annoUn￿ments and changes
in the CAB structure and the handover to Positive UK.
UK-CAB and community repwesentation
UK-CAB provides a unique collective community Vol￿ and broad range of lived expertise from many different
communities. We have a consliluent network lo represent and report lo. We ensure transparency with the wider
community and over the years many dodors, researchers and policy makers actively seek community views from the
UK-CAB.
Members have also been on several writing groups and tsken a lead role in the
production of the non-tethnical summaries for these guidelines. We also mentor several new wrib.ng group
representstives.
Infomation on this programme".
htt '.lth.ukcab.neUabouVcommuni
-re
resentativesl

HIV14ase
Report of thg trustses
Year ended 31 MARCH 2025
ACHIEVEMENT AND PERFORMANCE- continued
Full list of UK-CAB community representalwes".
htt s=Ilukcab.neVcommunit
-re
resentationlcommuni
-re
resentativesl
UK-CAB collaborations
UK-CAB works with professional bodies. These indude..
British HIV Associab"on IBHIVAI.
National HIV Nurses As50cialion {NHIVNAI.
A wide range of NHS HIV dinics.
NICE (National Institute for Health & Care EX￿llencE).
Medical Research Council Clinical Trials Unit
Medicines and Healthcare products Health Regulatory Agency.
Various dinical trial steering CL)mmittees with National Institute of HIV Research. universities and other b¢xJies.
International training and transition to African oryanisations
After more than a decade of dose collaborations, i-Base wound down involvement in a major project that developed
and updated community matenals in the Modern ART for Africa series. This projed supported the introduth.on of
optimised antiretroviral treatment in low- and middle-income countrie5.
It induded print, website and other resou￿$ that continued lo be developed and updated.
htt s'.IlmodernartForsouthafrica.co.za
During 2024, as part of the long-term goal to transition thi5 project to organisation5 based in South Africa, the Modern
ART project was passed lo Ezintsha who will continue to develop this wolk in partnership with the Treatment Action
Campaign
Website and Q&A services
The i-Base website continued to generate hvJh levels of use with approximately 200.000 to 300.000 web visits each
month, roughly indivKlual 3 million hits over the year. These figures vary a5 the algorithms used by search engines
induding Google are contsnually being updated.
The website continues to be assessed by people from more than 100 countries and territories globally. The countries
with highest use were South Africa125%1. India {17%1, USA {12%1, UK {10%) and Nigeria, Kenya and Uganda leach
with 7-8Yol.
From April 2024 to March 2025, the Q&A Servi￿ responded lo 7479 questions, with roughty 4960 email requests and
2519 online comments. This was roughly a 10% increase on the previous year and this is the third consecutive year
that demand has increased.
All infomation is monitored and logged anonymously and the regional distribution for the service remains similar to
previous years.. approximately 1 OQkn are from the UK and 90Qh are inlemalional.
The distribution of issues remains similar roughty haw the enquiries linked to HIV prevention with 30¥0 covering
lesling and transmission and 17% on PEP and PrEP. Alhough our primary focus is on treatment and care for people
living with HIV, the increasing use of the same dwgs for HIV prevention means thatwe also respond to these questions.

HIV14ase
Report of thg trustses
Year ended 31 MARCH 2025
ACHIEVEMENT AND PERFORMANCE- continued
The main treatment-related issues raised in emails. each accounted for about 4 10 70k of enquiries.
Pregnancy, breast feeding and infant prophylaxis
Treatment induding a¢￿$5 and starting treatment
Adheren￿ and resistance
Drug interactions
CD4 count, viral load and U=U
New diagnosis, symptoms and healthy lifestyle
Side effects
Disdosure and serodifferenl couples
This service is supported by grants from Gilead SCien￿s and Viiv Healthcare.
Websitel
All i-Base publications continue lo be published on the website and our online Q&A answered several thousand of
questions and online comments thts year.
The website was accessed by around 3 million people from 6.5 million hits. The sile has been accessed by people from
230 of the world's 241 countries and territories. It was designed and updated lo have fast access even wlh dial-up or
unreliable aC￿$S lo the Inlemel, induding on mobile phones and tablets.
The website is continually updated to be match guhlelines for access on handheld dewces.
FINANCIAL REVIEW
i-Base has a policy of maintaining unrestricted funds, which are the free reserves of the charity, al a level, which
equates lo approximately th￿MonthS lotsl expenditure. At the year end the free reseNes ex￿eded this.
During the first half of the financial year, we worked on re5truclured i-Base to run on a minimal budget. This included
changes in staffing, income and running costs. For roughty the first six months, i-Base continued some existing
services while winding down and handing over others. Many stsff wanted lo erther retire or focus on other activities
and we wort(ed with an independent CC￿su1tant to support transib"oning lo other organisalions or arranging planned
managed redundancies.
For the second six months, i-Base moved to a minimal emergency budget in order lo estsblish a more Secu￿ long-
term basis for the organisation. This induded giving up the rented offi￿. reducing print resources and moving lo
volunteer rather than paid staff. Thi5 was a150 in response to the restn"ctions funding support similar lo many other
organisalions in the HIV sector.
As a result. i-Base has continued many of the projects above on a much redU￿d budget but a150 established a
model that should sustain web-based servI￿S for al least the next two years.
The Trustees are pleased to report that during the year to 31 March 2025 i-Base succtssfully transitioned the African
support projects and the UK-CAB lo new organisats"ons. This induded transferring any ring-fen￿d funding for the
remainder of any grant period.
The direct infomalion serVI￿S lexduding publI￿tIonS) and the educational meetings for the UK-CAB were
supported by several grants from pham1a￿Utica1 companies totalling £24.183 from Gilead sryen￿s and Viiv
Healthca￿. This support i% a￿ayS independent of editorial content and programming which remains separate from
these awards.
Unreslricled funding for core costs remains difficutt to secure and has been one of the main risks lo the charity in
cent years. For example, i-Base hasn't received ststulory funding

HIV14ase
Report of thg trustses
Year ended 31 MARCH 2025
FINANCIAL REVIEW- continued
for many years and is unlikety to do so in the near future. However, cuts in NHS and Public Health England funding
means less support for peop￿ living with HIV and related infections from soaal servi￿. This is reflected in an HIV I-
Base
increase demand for our infomiation services and publications. i-Base aL%o tends to quickty respond to the need for
new reSoUr￿s, irrespects've of whether these are speafically funded.
This induded COlVtk19 and mpox in re(Ent years and this year il inVo￿ed responding to dramatic changes in the US
policy on international aid, including PEPFAR, Sin￿ 20 January 2025. This led to i-Base being active in several
intemalional ne￿orts, including providing infomiation lo more safely manage the difficults.es of closed sexual health
clinic and uncertain access to ART. We worked dosely wth WHO for online infr)rnialion and webinars and worked
with researcher5 on future management options including the potential for less than daily dosing.
Support from pharmaceub.cal companies is dependent on the priorities and governan￿ of the individual companies
and we are lucky that two of the leading companies value and support our wowk.
These funding i%sues have a￿ayS been the case and over the last 20 years there has been suffiaent flexibility for
some level of support to contribute towards oijr work. Most notabty. the number of companies In the field and their
community budgets have both decreased.
We still continue to apply for fvnding from a wider range of sources whenever this is in line with our objectives.
Total income for this year wa5 £67,757 compared to £315,715 in the previous year.
Nel reSoUr￿S expended for the year amounted to £299.973 compared to £ 496,183 in the
previous year.
Year end results show a deficit of £232,216.
FUTURE PLANS
i-Base was founded in 2000 to fill a gap that wasn't being mel by exists'ng Htv servi￿5 and organisation in the UK.
sin￿ then. we have continued lo focus on projects related to the evofving Scien￿ being HIV treatment from an
activist and peer-led perspective.
We still focus on providing specialised treatment infomialion that makes us an internationalty recognised and trusted
community organisalion. We have never been interested in duplicab.ng anything that is already being prOdU￿d.
Even running on a redU￿d budget. our semces and perspeth'ves are unique and enable us to effectively support
and Influen￿ the work of others.
Although based in the UK i-Base has always actively linked with sirnilar HIV organisations in other countries and
gions.
We hoped that restructuring i-Base and moving to an emergency budget wll enable the project to continue into the
future.

HIV l-Base
Report of the trustees
Year ended 31 MARCH 2025
STRUCTURE. GOVERNANCE AND MANAGEMENT
ststus
HIV i-Base is a eharilable company limited by guarantee. incorporated on 28 March 2000 and registered as 8 charity
on 8 August 2000.
The financial statements compty current statutory requirements, the Memorandum and Arti&s of Association
and the Statement of Recommended PractI￿- Accountsng and Reporting by Chanties.
Trustsgs
A new Trustee, Mr Christian Decle, was recruited in May 2024. The boa￿1 of Trustees are listed on page 1.
Trustees have a personal conneth.on and interest in i-Base's work as well as some experience of charity govemance.
An induction pack is provided for new Trustees, and they are invited to meetings and events organised by the
organisation and to develop involvement in all our woth.
Management
i-Base has a policy that reviews salaries on an annual basis following annual stsff reviews.
Although staffing is now redU￿d the organisation will link any future salaries to NJC salary scales
Risk Management
As part of the annual planning process, the trustees identify the major risks {ffinancial, operational,
governan￿lCoMplIanee and exlemal risks) facing the Charity over the coming year.
Each risk is assessed according to the likelihood. and polenkn.al impact and systems and procedures are agreed to
manage those risks which are implemented by the trustees and staff.
Some of the main risks facing the charity are detsiled below arKI how these risks are being contained..
Fundraising for unreslricled fijnds. Mib"gation indudes a focus on developing new income streams and
relationships and dose monitoring of income and expenditure. Moving lo a redU￿d budget means that the
remaining risks in this category are assessed as medium. This is in spite of redU￿d funding opportunities.
Moving to a virtual Offi￿ Spa￿ from 1 September 2024 signfficantly redutxl running costs.
Approved byorderof the board of trustees on.................................................. and signed on its behalfby".
W F M Stokes

HIV l-Base
Independent examine￿5 report
Year ended 31 MARCH 2025
l ￿pOrt lo the charity Iruslees on my examination of the accounts of the charity for the year ended 31 March 2025,
which are sel out in the attached Slatemenl of Finanaal Actsvitses. the Balance Sheet and the related notes.
Responsibilities and basis of report
As the trustees of the charitable company (and also its direclors for the purposes of company lawl, you are
responsible for the preparation of the finanryal statements in accordan￿ the requirements of the
Companies Act 2006.
Having satisfied mysew that the financaal ststements of the tharitsble company are not required lo be audited
under Part 16 of the Companies Act 20￿ and are eligible for independent examination. I report In respect of
my examination of the charitable company s finanaal statements carried out under section 145 of the Charities
Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under
section 145{5){bl of the Charities Act 2011.
Independent eXarnine￿S staternent
I have completed my examination. I confimi that no material matters have come to my attention in connection with the
examination giving me cause to believe that in any material respect..
accounts'ng records WEre not kept in respect of the thantsble company as required by section 386 of the
Companies Act 2006.
the financial statements do not accord those records., or
the financial slalemenls do not comply with the accountsng requirements of section 396 of the Companies
Act 2006 other than any requirement that the financial ststements give a true and fair view, which is not a
matter considered as part of an independent examinab"on', or
the financial statements have not been prepared in accordance the methods and prinaples of the
Statement of Recommended Practice for accounting and reporting by charib'es applicable lo charities
preparing their finanaal slalemenls in accordance with the Financial Reporting Stsndard applicable in the
UK and Republic of Ireland (FRS 1021.
I have no con￿MS and have come across no other rnatte￿ in connection with the examination to which attention
should be drawn in this report in order to enable a prorer understsnding of the accounts to be reached.
J HovArd FCA
Azets AuditSer4ices
nd
2 Floor, Regis House,
45 King William Street
London,
EC4R 9AN
Dale

HIV l-Base
Statement of financial activities (incorporating an income and expenditure account)
Year ended 31 MARCH 2025
Notes
Unrestricted
Funds
Restricted
Funds
Total
2025
Total
2024
Income:
Donations and legac￿5
Investsnenl income
9,934
2,196
55,627
65,561
2,196
310,719
4,996
Total income
12.130
55,627
67,757
315,715
Expenditure:
Raising funds
4,909
4,909
28,306
Charitable aclivilie5
209,158
85,906
295,(
467,877
Total resources expended
214.067
85,906
299,973
496,183
Net incomgllexpenditure) before
transfers
{201,9371
130,2791
{232,9731
{180,4681
Transfers be￿een funds
Net movement in funds
(201.937)
130.2791
{232,9731
{180.468)
Fund balan￿S brought forward
306,697
30,771
337,468
517,936
Fund balances carried foThvard at 31
MARCH 2025
12
104.760
492
105,252
337.468
The notes on pages 13 to 21 fomi part of these financial statements.
10

HIV l-Base
Balance Sheet
As at 31 MARCH 2025
2025
2024
Notes
Fixed assets
Tangible fixed assets
2.451
4,089
Current assets
Debtors
Cash al bank and in hand
10
11,436
110,072
26,970
358,426
121.508
385,396
Creditors: Amounts falling
due wthin one year
11
(18,707)
152,0171
Net current assets
105,801
333,379
Net assets
105.252
337.468
Funds
Reslricled funds
Unrestricted funds
492
104,760
30,771
306,697
13
105,252
337.468
The company is enb.lled to exemptson from audit under seth.on 477 of the Compan￿$ Act 2006 for the year ended 31
March 2025.
The members have not required the company to obtsin an audit of its finanryal statements for the year ended 31 March
2025 in accordan￿ with sedion 476 of the Companies Act 20(k5.
The directors ad(nowledge their responsibilities for..
al Ensuring thatthe company keeps aco)unting records which o)mptywith section 386 and 387 ofthe companies
Act 2006 and
bl Preparing financial statements which gNe a true and fair view of the stslemenl of affairs of the company as al
the end of each financial year and of its surplus or defiut for each finanaal year in accordan￿ with the
requirements of sections 394 and 395 and which othe￿iSe comply the requirements of the Companies
Act 2006 relating to financial statements. so far a5 applicable to the company.
The financial statements have teen prepared in ￿cordan￿ with the specaal provisions of Part 15 of Companies Act
2006 relab.ng to small companies.
Approved by the Board on
and signed on their behalf by".
W F M Stokes
The notes on pages 13 to 21 fomi part of these financial statements

HIV l-Base
ststement of Cash Flows
As at 31 MARCH 2025
2025
2024
Note
Cash flow from operating activities
17
1250,550}
1168,7761
Net eash flow from operating activities
{250,550}
1168,7761
Cash flow from investing activities
Payments to acquire tsngible fixed assets
Interest re￿iVed
13,6681
4,99S
2,196
Net cash flow from investing activities
2,196
1,328
Net increase I Ideerease) in cash and cash equivalents
Cash and cash equivalents atthe beginning of the reporting
period
{248,354}
358.426
1167,4481
525,874
Cash and cash equivalents at the end of the reporting period
110,072
358,426
Cash and cash equivalents consists of:
Cash at bank and in hand
110,072
358,426
Cash and cash equivalents at end dats 2025
110,072
358,426
The notes on pages 13 to 21 fomi part of these ffinancial statements
12

HIV l-Base
Notes to the financial statements
Forthe year ended 31 MARCH 2025
Accounting policies
General infomiation and basis of preparation
HIV l-Base is a company limited by guarantee in the United Kingdom The liability of each member in the event
of winding-up is limited lo £10. The address of the registered Offi￿ is given in the charity information on page
8 of these financial stslements. The nature of the charity's operab.ons and prinupal activities are set out on
page 1.
The tharitable company constitutes a public tenefft entity as defined by FRS 102.
The financial statements have been prepared in accordance with Accounting and Reporting by Charities..
Statement of Recommended Practi￿ applicable lo charities preparing their accounts in accordance with the
Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 issued on 16 July 2014,
the Financial Reporting Standard applicable in the United lQ"ngdom and Republic of Ireland IFRS 1021, the
Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Practice a5 It applies from 1 January
2015.
The finanryal statements are prepared on a going ￿nCeM basis under the historical cost convenb"on. modified
lo indude ￿rtain items at fair value. The finan￿al statements are prepared in sterling which is the functional
currency of the charity.
The significant accounting polioes applied in the preparats.on of these finanual statements are sel out below.
These poliaes have been consi5tenUy applied to all year5 presented unless otherwise staled.
b}
Going Concem
The financial statements have been prepared on a going con￿rn basis as the trustees believe that no material
Un￿rtaIntieS exist. The trustees have considered the level of fvnds held and the expected level of income and
expenditure for 12 months from authorising these finanoal statements. The budgeted income and expenditure
is sufficient with the level of reserves ft)r the charity to be able to conts.nue as a going concern.
Fund accounting
Funds held by the tharity are either..
Unrestricted general funds- these are funds which can be used in accordance with the charitable objects at
the discretion of the trustees.
Restricted funds- these are funds that can onty be used for particular restricted purposes within the objects
of the charity. Reslriclions arise when specffied by the donor or when funds are raised for the particular
reslricled purposes.
Further explanath?n of the nature and purpose of each fund is included in the notes to the finanaal statements.
13

HIV l-Base
Notes to the financial ststements
Forthe year ended 31 MARCH 2025
Accounting policies- continued
d}
Income
All incoming resources are including in the Statement of Financial Activib"es ISOFAI when the charity is legally
enlided to the income after any performance conditions have been met, the amount can be measured reliably
and it is probable that income will be r￿1ved.
Donation income induding grants.. are recognised in full in the Ststemenl of Finanaal Aclivf(ies in the year in
which they are recewable. Such in(x)me is only deferred when the donor specifies that the grant must only be
used in future accountsng periods. Grants re￿iVed for speaffic purposes are treated as reslricled funds.
Investment income is included ￿en receivable.
Resources expended
All expenditure is accounted for on an acuuals basis and has been classified under heading that aggregate
all costs related to the cat￿ory. Expenditure is recognised where these is a legal or constructive obligation to
make payments lo third parbes, it is probable that the settlement wll be required and the amount of the
obligation can be measured reliably. The irrecoverable element of VAT ts induded with the item of expenses
lo which it relates. 11 is calegorised under the following headings..
Costs of raising funds are those costs incurred in attracting grants and donation income.
Charitable expenditure comprise of those costs incurred by the charty in the delivery of ils activities and
services for its benefiaaries. It indudes both costs allocated direclly to suth activities and those costs of an
indirect nature ne￿Sary to support them.
Stsff costs are allo(3ted betsveen costs headings according to the fvncb.on of each employee.
Support costs allocation
Support costs are those Ihal assist the work of the charity but do not direcuy represent charitable activities
and indude governance cxists. administrative office funth.on costs. depreryation and premises costs. They are
incurred directly in support of expenditure on the objects of the charitable company.
Governance costs comprise all ￿$ts involviThJ the public a￿Un￿bility of the charity and indude statutory
independent examination fees.
Support and Govemance costs have been allocated across the charitsble actimties using various per￿ntsge
allocations.
gl
Tangible fixed assets
Tangible fixed assets are staled at cost less accumulated depreaation
Depreciation is provided on all tangible fixed assets, at rates calculated lo write off the cost of each asset over
their esb'mated useful lives 85 follo￿-.
0￿1￿ equipment
40% reducing balan￿ basis
Individual fixed assets costing £200 or more are c2pitslised al cost.
h}
Debtors
Grants repayable and other debtors are recognised at the setuemenl amount due. Prepayments are valued
at the amount prepaid.
14

HIV l-Base
Notes to the financial ststements
Forthe year ended 31 MARCH 2025
Accounting policies- continued
Cash at bank and in hand
Cash al bank and ￿sh in hand includes cash and short term highly liquid inveslments with a short maturity of
three months or less from date of acquisitions or opening of the deposit or similar account.
Creditors
Creditors are recognised when there is a present obligat.on resulting from a past event that will probably result
in the transfer of funds to a third party and the amount due to settle the obligation can be measured or
estimated reliably.
other creditors and accruals are recognised at their settlement amount due.
kl
Financial instruments
The charity only has assets and finanaal liabilities of a kind that qualify as basis financial instruments. Basic
financial instruments are initially recognised at transaction value and subsequenly measured al their
settlement value with the ex￿ptIOn of bank loans which are subsequently measured at amorti5ed cost using
the effective interest method.
Operating lea$e$
Rentals payable under operating lease5 are charged to the Statement of Finan￿al Activities as incurred over
the temi of the lease
Forgign currency
Assets and liabilities in foreign currencie5 are translated into sterling at the rates of exchange ruling al the
balance sheet dale. Transacb"ons in foreign currenoes are translated into stet1ing al the rate ruling on the date
of the transaction. Al exchange differences are reflected in the Statement of Financial ActThiities.
Tax
The charitable company is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010
and therefore it meets the definits.on of a charitsble company for UK corporation tax purposes. Accordingly,
the charty is potenlialty exempt from tsxalion in respect of income or capitsl gains r￿1Ved within categories
covered by Chapter 3 Part11 Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains
Act 1992, to the extent thal such income or gains are applied exdusNety to charitable purposes.
Pensions
The charity contributes to a defined contribution pension scheme for employees. The assets of the scheme
are held separately from those of the Charity in independendy administered funds. The pension cost charge
represents contributions payable by the Charity to the scheme.
15

HIV l-Base
Notes to the financial ststements
Forthe year ended 31 MARCH 2025
pl
Judgements and key sources of estimation uncertainty
Accounting eslimales and judgements are continually evaluated and are based on historical exper￿n￿ and
other factors. induding expectab.ons of ftjture events that are belEved to be reasonable under the
circumStan￿s.
The following judgements lapart from those involving eslimatesl have been made in the prO￿sS of applying
the above accounting wlicies that have had the most sgnificant effect on amounts recognised in the finanryal
statements..
Useful economic lives of tangible assets
The annual depreryation charge for tsngIb￿ assets is sensitive to changes in the esb"mated useful economic
lives and residual values of the assets. The useful economic lives and residual values are fE-assessed
annually. They are amended when necessary to rellect current eslimales, based on technological
adVan￿Ment, future invesknents, economic ulilisation and the physical condits.on of the assets. See note 9
for the carrying amount of the propety. plant and equipmenL and note g for the usefvl economic lives for each
class of assets.
There are no key assumptions conceming the future and other key Sou￿$ of estimation un￿rtainlY al the
reporting dale that have a significant risk of causing a material adjustment lo the carrying amounts of assets
and liabilities within the next ffinanaal year.
Donations and legacies
Unrestricted
2025
Restricted
2025
Totsl
2025
Total
2024
Individual, charitable, corporate and
intemational donations.
9.934
55,627
65.561
310,719
9.934
55,627
65.561
310,719
In 2024, £155,832 of the donations and legaae5 income was attributable to the restricted lunds, and the
maining £154,887 was attributab￿ lo the Un￿$tr￿led funds.
Investment incon
Unrestricted
2025
Restricted
2025
Total
2025
Totsl
2024
Bank interest
2,196
2.196
4,996
2.196
2,196
4,996
In 2024, all £4,996 of the investment income was attribU1ab￿ to the unrestricted funds.
Raising funds
Unrestricted
2025
Restricted
2025
Totsl
2025
Totsl
2024
Cost of generats'ng voluntary income
4,￿9
4,909
28,306
4.909
4,909
28,306
In 2024, 811 £28,3[￿ of the CL)St of raising funds was attributable to the unreStr￿￿j funds.
16

HIV l-Base
Notes to the financial ststements
Forthe year ended 31 MARCH 2025
Charitable activities
Unrestrieted
2025
Restricted
2025
Total
2025
Total
2024
Information services
121,516
8,863
77,010
130,5T9
77.010
87,441
33
184,917
35,688
247,107
165
UKCAB
Research and community development
AFROCAB
Rainwater
87,441
209,157
85,9C
295.063
467,877
In 2024, £166,302 of the expenditure in relation to charitable acbvities was attributable to the restricted
fund, with the remaining £301,575 being attribUtsb￿ to the unrestricted fund.
Analysis of expenditure
Direct
Costs
Support
Costs
(note 6.1 }
Total
2025
Total
2024
Cos15 of generating voluntary income
Information services
4,909
108,969
45,802
85.711
4,909
130,5T9
77.010
87,441
33
28,306
184,917
35,688
247.107
165
21,610
31,208
1.730
33
UKCAB
Research and community development
AFROCAB
Rainwater
54.581
245.391
299,972
496.183
In 2024, £430,448 of expenditure was attribulable to direct costs, wrf(h the remaining £65,735 being
attributable to support costs.
Support costs
Totsl
2025
Totsl
2024
Bank charges
Communications
Computer costs
Consultancy
Depreciab"on
Postage, stationery and sundries
Rent, rates and insuran
staff costs
Subscriptions
Travel, Subsisten￿ & conference attendan
Govemance eosts:
Accountancy costs
Independent examination
Auditors remuneration
365
606
2,455
10,878
1.638
8,702
17,622
196,336
96
13
497
1,925
2,808
210
2,727
2,953
37,854
1,652
96
250
3.430
3,250
7,203
7,560
245,391
65,735
17

HIV l-Base
Notes to the financial ststements
Forthe year ended 31 MARCH 2025
Staff costs and remuneration
2025
2024
Gross wages and salaries
Employerfs national insurance costs
Pension Contributions
124,883
8,991
3.511
218,896
17,676
8,799
137,385
245,371
Number
Number
The average number of employees during the year
Calculated on a full time equivalent basi5, wa5..
One employee received remuneration arnounting to more than £60,000 in the year (2024.. two).
Trustees received no remuneratson and were not reimbursed for any of their expenses in the year.
As of 31 March 2025, the key management of the charitable company comprise one of the co-founders.
The total employee benefits of the key management personnel of the charitsble t￿MpanY were £122,068
12024.. £202,469).
Net incomingl{outgoingl resources for the year
2025
2024
This is staled after charging..
Depreaation
Auditors, remuneration- audit servi￿5
Auditors, remuneration- non audit services
Independent examination
Operating lease rentals- property
1,638
2,727
7,560
1,926
3.250
11,750
23,500
18

HIV l-Base
Notes to the financial ststements
Forthe year ended 31 MARCH 2025
Tangible fixed assets
O￿lCe
equipment
Cost
Al 1 April 2024
Additions
Disposal
36.609
At 31 MARCH 2025
36.609
Depreciation
Al 1 April 2024
Charge for the year
Disposal
35.520
1,638
At 31 MARCH 2025
34,158
Net book value
At 31 MARCH 2025
2.451
At 31 March 2024
4,089
10.
Debtors
2025
2024
Grants repayable
Prepayments and accrued income
Other debtors
2.500
8,145
791
15,818
10,420
732
11.436
26,970
11.
Creditors: amounts falling due wtlhin one year
2025
2024
Amounts payable
Taxation and social security
other creditors
Accruals and deferred income {note 11.1)
9,163
6,204
3,177
33,473
18.707
18.707
52,017
12.
Analysis of net assets between fvnds
Unrestricted
funds
Restricted funds
Total
funds
Tangible fixed assets
Current assets
Current liabilities
2,451
121,016
118.707)
2,451
121,508
118,7071
492
104.760
492
105.252
19

HIV l-Base
Notes to the financial ststements
Forthe year ended 31 MARCH 2025
13.
Statement of funds
1 April
2024
Ineoming
resources
Resources
expended
Trnnsfer
31 MARCH
2025
Restricted funds
AFROCAB
UKCAB
Information services
Research & community
development
Unrestricted funds
General
33
30.271
467
{33}
177.010}
18,8631
46.739
8,888
492
306,697
12,130
1214,067)
104,760
Total Funds
337.468
67.757
(299.973)
105.252
AFROCAB:
Funds held on behalf of Afrocab relate lo grants made to Afrocab by various donors lo enable them lo establish
a nelwork of HIV positive people and advocates across Su&Saharan Africa based loosely on the UKCAB
network established in the UK by HIV l-Base. The group organises meetings on HIV treatment, access to
treatment and other topics as well as working with intemalional organisations such as the WHO to canvas
opinions from HIV positive people and advocates.
UKCAB:
Restricted funds relating to the UKCAB are those donated by a number of donors for the specrfic purpose of
covering attendance costs at UKCAB meetings for those delegates from outside London. These include travel,
accommodation and other expenses such as childcare costs.
Research & community development:
Restricted funds relating lo Community Outreach Overseas are those granted by WITS RH and HIV Institute
for the specific purpose of covering costs relating lo public3b.ons such as print and desvJn costs, travel to
meetings, accomm¢Jdation and other expenses such as ground tran5porL
20

HIV l-Base
Notes to the financial ststements
Forthe year ended 31 MARCH 2025
13.1 Statement of funds- Prioryear
1 April
2022
Ineoming
resources
Resources
expended
Transfer
31 March
2024
Restricted funds
AFROCAB
UKCAB
Infomialion servi￿$
Research & community
development
33
40,741
467
33
30,271
467
25.218
44.535
86,079
135.688}
144.535)
186,0791
Unrestricted funds
General
476,695
159,883
1329,8811
306,697
Totsl Funds
517.936
315.715
(496.183)
337.468
14.
Operating lease ¢ommitn*nts
2025
2024
The minimum annual rentals under operating leases are as follow5..
Within one year
Be￿een one and five years
13,583
13,583
15.
Related party disclosure
There were no related paty transaction for the current year or the prior years.
16.
Ultimate controlling party
The charitable company is considered to have no ullimale controlling party-
17.
Re¢on¢iliation of net incom91lexpenditure) to net cash flow from
operating activities
2025
2024
Nel incomellexpenditurel for year
Interest receivable
Depreciation of tsngible fixed assets
Disposal of tangible fixed assets
Ilncreasel I decrease in debtors
Increase I Idecreasel in creditors
1232,2161
{2,19S)
1,638
1180,4681
14,9961
2,727
51
118,4681
32,378
15.534
133,310}
1250,550}
1168,7761
21